4.4 Article

Management of interstitial lung disease (ILD) in myositis syndromes: A practical guide for

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.berh.2022.101769

关键词

Myositis; Interstitial lung disease; Management; In flammatory myopathies

资金

  1. MRC-EMINENT award
  2. MRC NIRG
  3. Department of Health's NIHR Biomedical Research Centres funding scheme

向作者/读者索取更多资源

Inflammatory myopathies are a diverse set of clinical syndromes with variable manifestations, and interstitial lung disease (ILD) is a major contributor to morbidity and mortality in myositis patients. The treatment approach for myositis-ILD involves immunomodulation and the option to add antifibrotics to slow down fibrosis progression. Early identification and multidisciplinary collaboration are crucial for the assessment and management of myositis-ILD.
Inflammatory myopathies are heterogeneous clinico-serological syndromes, with variable clinical manifestations. Interstitial lung disease (ILD) is a major cause of morbidity and mortality in pa-tients with myositis. The clinical manifestation of myositis-ILD is heterogeneous, e.g., with acute-on-chronic presentations, as well as the chronic aftermath of acute disease. Here, we have largely divided myositis-ILD into three main prognostic groups which require different treatment approaches: mild-moderate (sub-acute), severe or progressive (acute or subacute) and rapidly pro-gressive, life-threatening. In current clinical practice, the treatment of myositis-ILD involves immunomodulation in an induction -maintenance treatment paradigm. There is now an option to add antifibrotics to slow the progression of established fibrosis in selected cases with chronic progressive phenotype. Here, we describe current concepts in myositis-ILD and aim to provide a practical guide for clinicians on how to approach assessment, including early identification of ILD, phenotyping of patients according to clinical trajectory and likely prognosis and stratified management adopting multi-disciplinary cross-speciality exper-tise, with close collaboration between rheumatology and respira-tory physicians.(c) 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据